Overview

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. - Primary Endpoint: Relapse-free survival (RFS) - Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile

Phase:

Phase 2

Details

Lead Sponsor:

TTY Biopharm

Collaborators:

Chang Gung Memorial Hospital
National Cheng-Kung University Hospital
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan